🇺🇸 AMGN — Amgen Inc.

Salud Mantener
← Volver

Precio actual

460,28 USD

Máx. histórico

478,48

1 días

Split 2:1 del 22/11/1999

Caída desde máximo

-3,80%

Rango 52 semanas

312,39 – 483,99

Variación hoy

-3,80%

Cierre anterior

478,48

Rango de hoy

459,65 – 483,99

Volumen hoy

4.073.505

Peor caída histórica

-78,03%

17/06/1983 → 19/11/1984

Recuperado en 487 días

Volatilidad anualizada ⓘ

37,46%

Información
Nombre completo
Amgen Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Drug Manufacturers - General
Empleados
31.500
PER ⓘ
26,68 (puede no estar actualizado)
Dividend yield
2,11% (puede no estar actualizado)
Precio objetivo analistas
404,32 USD (puede no estar actualizado)
Primera cotización
17/06/1983
Precio actualizado
hace 1 día
Sobre la empresa

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Dividendos repartidos Total últimos 12 meses: 9,9400 USD · Yield: 2,16%
Fecha de pago Importe por participación
21/08/2026 2,5200 USD
15/05/2026 2,5200 USD
13/02/2026 2,5200 USD
21/11/2025 2,3800 USD
22/08/2025 2,3800 USD
16/05/2025 2,3800 USD
14/02/2025 2,3800 USD
18/11/2024 2,2500 USD
16/08/2024 2,2500 USD
16/05/2024 2,2500 USD
15/02/2024 2,2500 USD
16/11/2023 2,1300 USD
17/08/2023 2,1300 USD
17/05/2023 2,1300 USD
14/02/2023 2,1300 USD
Splits Registrados en el histórico de precios
Fecha Ratio
22/11/1999 2:1
01/03/1999 2:1
16/08/1995 2:1
11/09/1991 3:1
13/08/1990 2:1
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
04/04/2018 166,17 174,27 165,88 173,52 +3,15% 5,05% 3.796.700
03/04/2018 166,97 169,22 165,08 168,22 +1,31% 2,48% 3.374.000
02/04/2018 169,92 170,58 163,31 166,05 -2,60% 4,28% 4.759.800
29/03/2018 170,99 172,24 169,64 170,48 +0,01% 1,52% 3.769.800
28/03/2018 171,35 172,50 168,02 170,46 -0,40% 2,61% 4.545.900
27/03/2018 176,16 176,36 169,82 171,15 -2,31% 3,71% 3.963.100
26/03/2018 172,78 175,87 170,11 175,19 +3,40% 3,33% 4.217.100
23/03/2018 176,57 179,18 169,35 169,43 -3,78% 5,57% 4.529.600
22/03/2018 179,92 180,75 176,00 176,08 -3,03% 2,64% 3.553.000
21/03/2018 181,43 184,04 181,40 181,59 -0,24% 1,46% 2.531.100
20/03/2018 183,06 184,02 181,17 182,03 -0,28% 1,56% 2.582.200
19/03/2018 187,29 187,93 180,67 182,55 -3,02% 3,88% 3.970.400
16/03/2018 189,75 190,25 187,23 188,24 -0,80% 1,59% 16.878.400
15/03/2018 190,05 190,88 187,91 189,75 -0,43% 1,56% 3.320.500
14/03/2018 191,18 192,62 189,80 190,57 +0,43% 1,48% 3.613.300
13/03/2018 189,60 190,83 188,63 189,75 +0,24% 1,16% 4.712.900
12/03/2018 189,50 190,39 188,32 189,30 -0,94% 1,09% 6.972.400
09/03/2018 188,00 191,38 186,32 191,10 +2,11% 2,69% 5.674.100
08/03/2018 187,90 188,40 185,51 187,16 -0,20% 1,54% 9.192.600
07/03/2018 189,73 190,22 186,41 187,53 -1,48% 2,01% 7.009.900
06/03/2018 188,20 191,64 186,93 190,35 +0,12% 2,50% 18.446.500
05/03/2018 185,05 190,69 185,00 190,13 +2,73% 3,07% 15.187.800
02/03/2018 181,06 185,80 181,05 185,08 +0,98% 2,62% 19.115.500
01/03/2018 184,21 185,57 180,38 183,29 -0,26% 2,82% 11.757.800
28/02/2018 185,88 187,39 183,69 183,77 -1,09% 1,99% 4.544.000
27/02/2018 188,83 190,10 185,55 185,79 -1,44% 2,41% 5.016.100
26/02/2018 187,46 190,37 187,03 188,50 +0,98% 1,78% 4.943.600
23/02/2018 183,63 186,79 182,77 186,67 +2,31% 2,19% 4.163.400
22/02/2018 182,51 185,16 182,01 182,45 +0,01% 1,73% 3.868.200
21/02/2018 183,19 185,50 182,40 182,43 -0,30% 1,69% 4.054.600